Leica Microsystems and A Menarini Diagnostics extend distribution
agreement
7 August 2009
Leica Microsystems GmbH and A. Menarini Diagnostics S.r.l. have
signed a five-year agreement to extend their successful co-operation in
distributing Leica products in Europe.
According to this agreement, Menarini Diagnostics will continue to be
the exclusive distributor in key European countries for Leica
Microsystems’ automated immunohistochemistry (IHC) stainer, Leica Bond,
as well as Leica Microsystems’ Novocastra antibodies and reagents.
The Leica BOND is a flexible, fully-automated staining system for
immunohistochemistry-based cancer diagnosis. Used in combination with
Leica Microsystems’ well-known range of Novocastra antibodies, it allows
fast, reliable and consistent staining of tissue samples (biopsies) to
aid in the diagnosis and staging of cancer.
The distribution agreement succeeds a five-year contract between the
companies. “We are pleased to be able to continue our successful
partnership with Menarini Diagnostics. This partnership will allow our
joint customers to benefit from Menarini’s strong sales force and
customer support and from our world-class immunohistochemistry products.
This partnership is key to our goal to further increase our market share
in immunohistochemistry in Europe,” explains Dr. David Martyr, President
Leica Microsystems.
Dr. Crescenzio Izzo, Managing Director A. Menarini Diagnostics said:
“The renewal of this agreement confirms our approach to build strong
partnerships with customers and Leica Microsystems, a leading company in
R&D and Manufacturing of innovative product solutions.
Our expert, specialized distribution organization covers a large part
of the European diagnostics market. We have built our expertise in the
Immunohistochemistry field for almost 20 years and we employ about 300
highly skilled people in sales, technical services and application
support. Menarini takes its responsibility to the healthcare community
seriously and strives to always provide the best solutions to its
customers’ needs in the field of immunohistochemistry.”
Bookmark this page